Lotronex (alosetron) is a drug for the treatment of irritable bowel syndrome with diarrhea (IBS-D). It blocks serotonin signals that transmit sensory information (painful and non-painful) from the gut to the brain and helps to reduce diarrhea and belly pain. Alosetron has been approved for the use in women with severe diarrhea-predominant IBS. It is only prescribed under restricted use due to rare but potentially serious side effects. Use includes a Risk Management plan to help reduce potential serious outcomes of an adverse event.

FDA Approves Restricted Marketing of Lotronex

(June 7, 2002) The Food and Drug Administration (FDA) today announced the approval of a supplemental New Drug Application (sNDA) that permits marketing of Lotronex (alosetron hydrochloride) with restrictions through an established Prescribing Program for Lotronex™ (PPL). Lotronex may be prescribed only by physicians who have enrolled in the PPL. The drug's indication has been narrowed to be only for treatment of women with severe, diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed to respond to conventional IBS therapy. Limiting the use of Lotronex to this severely affected population is intended to maximize the benefit to risk ratio.

You MUST do 3 things if you are going to take LOTRONEX (From FDA Medication Guide):

1) Understand that LOTRONEX has serious risks.
2) Sign a Patient-Physician Agreement with your doctor.
3) Follow the directions in this Medication Guide.
If you can't do ALL of these, you should not take LOTRONEX.

Read this Medication Guide carefully before you sign the Patient-Physician Agreement and before you start to take LOTRONEX. Read the Medication Guide you get with each refill for LOTRONEX. There may be new information. This Medication Guide does not take the place of talking with your doctor.

What is the most important information I should know about LOTRONEX? Because of serious bowel side effects, including some deaths, seen with use of this drug, LOTRONEX is only for women who have very bad irritable bowel syndrome and whose main problem is diarrhea (diarrhea-predominant IBS). To decide if you want to use LOTRONEX, you need to know about possible side effects of LOTRONEX and how LOTRONEX may help your IBS. Very few patients have diarrhea-predominant IBS that is bad enough to consider using LOTRONEX.

Product information and prescribing information for physicians, pharmacists, and patients may be found at this Prometheus Lotronex web site.

What are Phases?

Treatment trials or studies are in phases:

  • Phase 1 tests a new drug or treatment in a small group to evaluate its safety, determine a safe dosage range, and identify side effects;
  • Phase 2 expands the study to a larger group of people to see if it is effective and to further evaluate its safety;
  • Phase 3 expands the study to an even larger group of people to confirm its effectiveness, monitor side effects, and collect information that will allow the drug or treatment to be used safely.
Medical and Treatment News
Industry Treatment News
Eluxadoline (Viberzi)
Eosinophilic Esophagitis Study
Linaclotide (Linzess)
Medical News
Medical News - Archive (2006-2013)
Special Events & Meetings
Press Releases
2017-0403 IFFGD Encourages People to See Their Doctor for Symptoms of IBS
2016-1115 GERD is More Than Simple Heartburn
2016-0801 Learn the Facts About Gastroparesis
2016-0405 Think You Have IBS? Find Out For Sure Before Starting a Treatment
2015-1123 Is it More than Simple Heartburn? Ask Your Doctor.
2015-7-30 Gastroparesis is a Hidden Medical Condition for Many
2015-0330 Online Survey Looks to Help Improve Outcomes for those with IBS
2014-1119 Persistent Heartburn May Be a Sign of GERD
2014-0826 Lack of Awareness of Gastroparesis May Impact Medical Care
2014-0326 IFFGD Marks IBS Awareness Month with Launch of Mobile App
2014-0225 IFFGD Research Grants to Study Gastroparesis
2013-1106 15 Tips for GERD Awareness Week
2013-0626 New DHA.org
2013-0412 IFFGD Presents 2013 Research Awards
2013-0401 Turning Attention to Returning Vets
2012-1109 Banish Frequent Heartburn by Burning More Calories
2012-0321 April is IBS Awareness Month: A Serious Issue for Veterans
2011-1130 Is Your Child's Reflux/Spitting Up A Point of Concern?
2011-0412 IFFGD Research Award Winners
2011-0329 IBS Signs You Should Not Ignore
2010-1118 GERD Difference
2010-0517 US House Resolution for IBS
2010-1001 Heartburn or GERD?
2009-1109 GERD at Night
2009-0417 IFFGD Research Award Recipients
2008-0331 Dealing with Digestive Disorders
2007-1118 When Is Simple Heartburn Not So Simple?
2007-0718 Proposed FDA Funding Applauded
2007-0401 IBS Myths
2006-1116 GERD & Holidays
2006-0418 Natl Commission
2006-0321 Women's Health
2006-0202 IBS or Something Else
2005-1125 GERD Costs
2005-0412 IBS Awareness
2004-1125 Heartburn & Heartache
2004-0929 Norton Honored
2004-0525 IBS Travel Tips
2004-0408 IBS Medical Care
2004-0101 IFFGD Conference
2003-1117 GERD Treatment
2003-0401 IBS Awareness
2003-0401 IFFGD Research Awards
2002-0423 IBS-C Treatment
2002-1102 Heartburn Caution
2002-0423 IBS in Real World
2002-0402 IBS & Lost Potential
2001-1119 Heartburn or Heart Attack
2001-0322 Patients First
1998-0401 IBS Millions Suffer
1997-1114 Research & Women's Health
Misunderstood Functional GI Disorders
IBS is No Joking Matter
For Media
Reporters' Guides
Media Contact Form

Our Mission

healthy family

Education and Research

Our mission is to inform, assist and support people affected by gastrointestinal (GI) disorders.

IFFGD works with patients, families, physicians, health care professionals, and others to broaden understanding about gastrointestinal disorders and support or encourage research.

Awareness Activities & Accomplishments

Advocacy Activities

IFFGD Research Awards